For the year ending 2025-12-31, AXSM had $7,580K increase in cash & cash equivalents over the period. -$93,885K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 638,496 |
| Cost of revenue (excluding amortization and depreciation) | 47,478 |
| Research and development expense recognized-Solriamfetol | 42,106 |
| Research and development expense recognized-AXS-05 | 55,312 |
| Research and development expense recognized-AXS-07 | 21,421 |
| Research and development expense recognized-AXS-12 | 8,482 |
| Research and development expense recognized-AXS-14 | 8,485 |
| Other research and development | 20,645 |
| General and administrative expense (excluding stock-based compensation expense) | 63,273 |
| Selling and marketing expense (excluding stock-based compensation expense) | 440,402 |
| Stock-based compensation expense | 93,752 |
| Loss (gain) in fair value of contingent consideration | -2,473 |
| Interest expense, net | -6,557 |
| Other segment items | 16,230 |
| Profit Loss | -183,174 |
| Adjustments and reconciling items | 0 |
| Net loss | -183,174 |
| Stock-based compensation expense | 93,752 |
| Amortization of intangible asset | 6,375 |
| Amortization of debt discount | 1,303 |
| Loss on debt extinguishment | -10,385 |
| Depreciation | 503 |
| Loss in fair value of contingent consideration | -2,473 |
| Gain from lease modification | 2,250 |
| Non-cash lease expense | 3,046 |
| Right-of-use asset amortization for finance lease | 2,186 |
| Accounts receivable, net | 82,463 |
| Inventories, net | 10,660 |
| Prepaid expenses and other current assets | 1,673 |
| Non-current inventory and other assets | 5,010 |
| Accounts payable | -6,460 |
| Accrued expenses and other current liabilities | 83,743 |
| Operating lease liability | -535 |
| Net cash used in operating activities | -93,405 |
| Purchases of equipment | 480 |
| Net cash used in investing activities | -480 |
| Proceeds from draw down of debt | 330,000 |
| Payment of debt issuance costs | 3,638 |
| Repayment of debt | 331,988 |
| Payments on principal portion of finance lease obligation | 2,124 |
| Proceeds from issuance of common stock upon financing | 67,904 |
| Cash paid for common stock issuance costs | 1,197 |
| Proceeds from issuance of common stock upon exercise of options and under employee stock purchase plan | 59,558 |
| Payment of contingent consideration | -9,940 |
| Payments of tax withholdings on stock awards | 7,110 |
| Net cash provided by financing activities | 101,465 |
| Net increase (decrease) in cash | 7,580 |
| Cash at beginning of period | 315,353 |
| Cash at end of period | 322,933 |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)